BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024

Rhea-AI Summary

BridgeBio Pharma, a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, will present at the Bank of America Merrill Lynch Global Healthcare Conference 2024.

The event is scheduled for May 15 at 3:00 pm PT in Las Vegas, NV. The presentation will be accessible via a live webcast on the company's investor relations website, with a replay available for 90 days.

Positive

• BridgeBio Pharma's participation in a significant industry conference highlights its active engagement within the healthcare sector.
• The live webcast and 90-day replay availability offer transparency and accessibility for investors.
• Presence at the conference may increase visibility and attract potential investors or partners.

Negative

• The press release does not mention any new product launches, partnerships, or clinical trial results, which may be seen as a missed opportunity to share impactful news.
• No financial or operational updates were provided, leaving investors without new data to assess company performance.

PALO ALTO, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of its management team will present at the Bank of America Merrill Lynch Global Healthcare Conference 2024 in Las Vegas, NV on Wednesday, May 15 at 3:00 pm PT.

To access the live webcast of BridgeBio’s presentation, please visit the “Events & Presentations” page within the Investors section of the BridgeBio website at http://investor.bridgebio.com. A replay of the webcast will be available on the BridgeBio website for 90 days following the event.

About BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc. (BridgeBio) is a commercial-stage biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers, and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn and Twitter.

BridgeBio Contact:
Vikram Bali
contact@bridgebio.com
(650)-789-8220

FAQ

When will BridgeBio Pharma present at the Bank of America Merrill Lynch Global Healthcare Conference 2024?

BridgeBio Pharma will present on May 15, 2024, at 3:00 pm PT.

How can I access BridgeBio Pharma's presentation at the Bank of America Merrill Lynch Global Healthcare Conference?

The presentation will be accessible via a live webcast on the 'Events & Presentations' page within the Investors section of BridgeBio's website.

Will the webcast of BridgeBio Pharma's presentation be available for replay?

Yes, a replay of the webcast will be available on the BridgeBio website for 90 days following the event.

What is the stock symbol for BridgeBio Pharma?

The stock symbol for BridgeBio Pharma is BBIO.

What kind of company is BridgeBio Pharma?

BridgeBio Pharma is a commercial-stage biopharmaceutical company focused on genetic diseases and cancers.